Johnson & Johnson (JNJ) Shares Up 53% in Past Year
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowJohnson & Johnson (JNJ) shares have gained 53% over the past year and are up 15% year-to-date. Leerink Partners upgraded JNJ's shares on May 13th, raising the price target from $252 to $265. The firm believes that JNJ's new drugs will contribute to revenue growth and share price performance. Additionally, JNJ has seen a 7.7% increase in share price over the past month amid market liquidity issues.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Johnson & Johnson (JNJ)
Johnson & Johnson is a healthcare giant spanning pharmaceuticals and medical devices, known for its deep drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier JNJ news
- J&J (JNJ) Expands US Rollout of TECNIS Cataract Lens
- Dividend Strategy Beats 4% Rule by Up to $430K Over 20 Years
- Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
- IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
- Dividend Portfolio Yield Impacts After Taxes for California Residents
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
